The ECM (extracellular matrix) skin booster market in South Korea is projected to surge from KRW 9.9 billion in 2025 to KRW 92.5 billion in 2026 and KRW 172.9 billion in 2027, representing a three-year compound annual growth rate of 318%, according to a recent report from Shinhan Investment & Securities. The rapid expansion signals a structural shift in the aesthetic injectables segment, moving beyond hydration-focused boosters toward tissue restoration, which is attracting attention from overseas buyers evaluating next-generation dermal bio-remodeling products.
Market signal
Shinhan analysts Kim Ji-young and Choi Seung-hwan stated in their report that ECM skin boosters represent a structurally growing industry driven by real demand, not a short-term trend. They noted a paradigm shift from regeneration induction to structural restoration, as consumer interest in natural skin quality improvement rises. The report estimates the entire domestic skin booster market (including PN, PLA, and ECM products) will reach KRW 308.6 billion in 2025, KRW 419.9 billion in 2026, and KRW 518.8 billion in 2027.
ECM segment growth and key products
ECM skin boosters are expected to increase their share of the total skin booster market from 3% in 2025 to 20% in 2026 and 28% in 2027. In Q1 2026, leading products showed strong sales: Lituo (by L&C Bio) recorded approximately KRW 8.1 billion, up 113% quarter-on-quarter, and Cellr-DM (by Hans Biomed) reached KRW 4.3 billion, up 15%. Other domestic players are entering the space: GC Green Cross Wellbeing launched 'G-Cell Rebonne', and Hugel secured domestic rights for Cellr-DM through a partnership with Hans Biomed.
Supply-side dynamics and capacity expansion
Analysts identified demand expansion, capacity (CAPA) increases, and accelerated clinic penetration as key growth drivers. "The core bottleneck is supply, not demand," Kim said, noting that both L&C Bio and Hans Biomed are pursuing phased CAPA expansions within the year. "Aggressive CAPA expansion indicates manufacturers highly value the structural growth potential of the ECM market, while also securing raw material supply stability and organizational networks."
Regulatory and channel signals
ECM skin boosters currently operate in a regulatory gray area. Because they use human-derived tissue, they are handled under the Human Tissue Safety and Management Act rather than medical device regulations, meaning they are not required to undergo clinical trials for safety and efficacy—unlike conventional skin boosters classified as medical devices. The Ministry of Food and Drug Safety (MFDS) has formalized plans to issue guidelines for human-tissue-based products within the year. Kim noted that while regulatory risk may dampen short-term sentiment, clear standards are expected to resolve uncertainty and support safe market growth. "Discussions are likely to focus on strengthening safety management and clarifying advertising, labeling, and usage standards, rather than blocking the ECM skin booster market entirely," he added.
What buyers should watch
Overseas distributors and clinic buyers should monitor the MFDS guideline timeline, as it will shape the compliance framework for ECM-based injectables. The rapid domestic adoption and capacity expansion by Korean manufacturers suggest potential for export-ready supply chains. Products like Lituo, Cellr-DM, and G-Cell Rebonne represent early movers in a category that could follow the global trajectory of PN and PLA boosters. Buyers evaluating dermal bio-remodeling portfolios should assess regulatory pathways in their own markets and consider partnerships with Korean OEMs that have secured tissue-bank licenses and scalable production.
Source: Read the original report | Published: June 11, 2026